Univar’s Cufence Approved In EU For Wilson’s Disease, But Loses Orphan Status
Cufence, which has just been authorized for EU-wide marketing, is one of two trientine products for Wilson’s disease to lose their orphan designation.
You may also be interested in...
An EU court has upheld a decision to revoke the orphan designation awarded to GMP-Orphan's trientine product for Wilson's disease, saying that the product no longer met the “significant benefit” criterion on the grounds of lack of availability of another drug. The case has raised questions about the level of evidence needed to justify a significant benefit.
The CHMP has recommended 11 products for approval at its latest meeting, including four orphan medicines, three biosimilars and two generics. It also recommended harmonizing the product labeling for two etoposide products.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.